Paul Chaplin, Bavarian Nordic president and CEO

Bavar­i­an Nordic se­cures BAR­DA con­tract for small­pox vac­cine

It seems that small­pox vac­ci­na­tion pro­duc­tion is weigh­ing on the mind of the US gov­ern­ment. And man­u­fac­tur­er Bavar­i­an Nordic is the lat­est com­pa­ny to ben­e­fit.

Just a few days af­ter Emer­gent, a com­pa­ny that has made gov­ern­ment con­tracts its lifeblood, ac­quired the ex­clu­sive rights to Tem­bexa from Chimerix, with a $225 mil­lion cash pay­ment and an ex­pect­ed BAR­DA con­tract, the agency has of­fered a con­tract for small­pox vac­cine pro­duc­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.